Advances in HemophiliaHemophilia in the 21st century: tremendous progress, tremendous opportunity
Section snippets
Financial disclosure/conflict of interest
Dr Fogarty has received consulting fees from Bayer Healthcare, Baxter/Baxalta, Biogen, Chugai, CSL Behring, NovoNordisk, and Pfizer, Inc; has received research support from Bayer Healthcare, Baxter/Baxalta, Biogen, CSL Behring, Pfizer, Inc, and Spark Therapeutics; and is an employee of Pfizer, Inc.
References (23)
The tragic history of AIDS in the hemophilia population, 1982–1984
J Thromb Haemost.
(2006)- et al.
Mortality Rates, life expectancy, and causes of death in people with haemophilia A or B in the United Kingdom who were not infected with HIV
Blood
(2007) Hemophilia in classic Rabbinic texts
J Hist Med Allied Sci
(1994)Review of American Publications in Medicine, Surgery, and the Medical Repository
(1803)Die Gelenkerkrankungen bei Blutern mit besonderer Berücksichtigung der Diagnose
Chirugie
(1890)- et al.
Blood-induced joint damage in hemophilia
Semin Thromb Hemost.
(2003) - et al.
Prophylaxis in older Canadian adults with hemophilia A: lessons and more questions
BMC Hematol
(2015) - et al.
Changes in the life expectancy of patients with severe haemophilia A in Finland in 1930-79
Br J Haematol.
(1982) Thirty years of haemophilia treatment in Oxford
Br J Haematol
(1967)- et al.
Christmas disease: a condition previously mistaken for haemophilia
Br Med J.
(1952)
Plasma thromboplastin component (PTC) deficiency; a new disease resembling hemophilia
Proc Soc Exp Biol Med.
(1952)
Cited by (0)
Copyright © 2016 Elsevier Inc. All rights reserved.